ALKS

Alkermes Plc

Add to Watchlist

Advanced Chart

26.130

-0.4(-1.508%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

26.625

Open

26.550

VWAP

Vol

1.69M

Mkt Cap

4.31B

Low

26.050

Amount

EV/EBITDA(TTM)

8.17

Total Shares

169.22M

3.42B

EV/OCF(TTM)

6.63

P/S(TTM)

2.90

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

380.77M

-11.44%

0.562

-46.51%

354.58M

-6.23%

0.460

-37.05%

341.30M

-14.49%

0.377

-46.15%

Estimates Revision

The market is revising Downward the revenue expectations for Alkermes plc (ALKS) for FY2025, with the revenue forecasts being adjusted by -0.42% over the past three months. During the same period, the stock price has changed by -6.38%.

Revenue Estimates for FY2025

Revise Downward

-0.42%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-4.84%

In Past 3 Month

Stock Price

Go Down

-6.38%

In Past 3 Month

14 Analyst Rating

55.15% Upside

Wall Street analysts forecast ALKS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALKS is 40.54 USD with a low forecast of 34.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

5 Hold

0 Sell

Moderate Buy

55.15% Upside

Current: 26.130

Low

34.00

Averages

40.54

High

46.00

55.15% Upside

Current: 26.130

Low

34.00

Averages

40.54

High

46.00

Stifel

Buy

maintain

$42

2025-07-21

Reason

Stifel

Price Target

$42

2025-07-21

maintain

Buy

Reason

Stifel reiterates a Buy rating and $42 price target on Alkermes shares after the company reported top-line data for ALKS2680, or "Alixorexton," in Narcolepsy Type-1. While this study was widely expected to succeed given prior Phase 1b data, the results "look clearly positive with many key clinical endpoints hitting statistical significance at all doses," the analyst tells investors. On safety, the disclosure was fairly high level, but the press release specifically noted no treatment-related signals in hepatic/renal parameters, vital signs or ophthalmic exams and 95% of patients who participated in the trial entered the open-label extension, which is "always encouraging," the analyst added.

Jefferies

Buy

maintain

$50 -> $54

2025-07-21

Reason

Jefferies

Price Target

$50 -> $54

2025-07-21

maintain

Buy

Reason

Jefferies raised the firm's price target on Alkermes to $54 from $50 and keeps a Buy rating on the shares after the company released topline Phase 2 data for alixorexton in narcolepsy type 1. The firm, which continues to be positive on the class, is increasing its view of the odds of success in NT1 patients to 90% from 80% and its adjusted peak sales estimate for ALKS-2680 across narcolepsy types 1 and 2 and idiopathic hypersomnia to $1.6B from $1.5B.

Goldman Sachs

NULL -> Buy

initiated

$43

2025-07-15

Reason

Goldman Sachs

Price Target

$43

2025-07-15

initiated

NULL -> Buy

Reason

Goldman Sachs initiated coverage of Alkermes with a Buy rating and $43 price target. The firm says the company's "mature" portfolio of neuropsych assets are on track to achieve fiscal 2025 guidance while its orexin receptor 2 portfolio updates will drive share appreciation. Goldman is optimistic on the shares into the upcoming data.

UBS

Ashwani Verma

Neutral -> Buy

upgrade

$33 -> $42

2025-06-18

Reason

UBS

Ashwani Verma

Price Target

$33 -> $42

2025-06-18

upgrade

Neutral -> Buy

Reason

UBS analyst Ashwani Verma upgraded Alkermes to Buy from Neutral with a price target of $42, up from $33. The firm says its recent physician survey drives confidence that ALKS-2680 is well positioned to potentially establish itself as an attractive treatment option in narcolepsy idiopathic hypersomnia. The shares re current levels are pricing in $1.2B in 2030 sales versus UBS's base case of $1.8B, the analyst tells investors in a research note. The firm believes data readouts in the second half of 2025 from Alkermes and peers can drive excitement behind the orexin class.

Needham

initiated

$45

2025-05-28

Reason

Needham

Price Target

$45

2025-05-28

initiated

Reason

Deutsche Bank

David Hoang

Strong Buy

Maintains

$40 → $52

2025-03-27

Reason

Deutsche Bank

David Hoang

Price Target

$40 → $52

2025-03-27

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Alkermes Plc (ALKS.O) is 0.00, compared to its 5-year average forward P/E of 98.21. For a more detailed relative valuation and DCF analysis to assess Alkermes Plc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

98.21

Current PE

0.00

Overvalued PE

246.94

Undervalued PE

-50.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.50

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

74.51

Undervalued EV/EBITDA

-73.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Overvalued

5Y Average PS

3.59

Current PS

6.47

Overvalued PS

4.50

Undervalued PS

2.69

Financials

Annual

Quarterly

FY2025Q1

YoY :

-12.52%

306.51M

Total Revenue

FY2025Q1

YoY :

-68.15%

13.79M

Operating Profit

FY2025Q1

YoY :

-42.32%

22.46M

Net Income after Tax

FY2025Q1

YoY :

-38.10%

0.13

EPS - Diluted

FY2025Q1

YoY :

+594.82%

88.70M

Free Cash Flow

FY2025Q1

YoY :

+1.19%

83.95

Gross Profit Margin - %

FY2025Q1

YoY :

+39.27%

31.81

FCF Margin - %

FY2025Q1

YoY :

-34.08%

7.33

Net Margin - %

FY2025Q1

23.99

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

210.1K

USD

3-6

Months

12.1M

USD

6-9

Months

8.3M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.0M

Volume

6-9

Months

724.4K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

301.5K

Volume

Months

6-9

6.1M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

210.1K

USD

3-6

Months

12.1M

USD

6-9

Months

8.3M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ALKS News & Events

Events Timeline

2025-07-21 (ET)

2025-07-21

13:59:02

Alkermes narcolepsy trial results 'encouraging' for Centessa, says Leerink

2025-07-21

12:06:07

Alkermes data has limitations, but 'strong,' says H.C. Wainwright

2025-07-21

09:42:38

Needham sees Alkermes trading up on today's narcolepsy data

News

9.0

07-21Benzinga

Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study

2.0

07-21CNBC

Stocks making the biggest moves midday: Block, SolarEdge, Cleveland-Cliffs, Verizon & more

4.0

07-21Benzinga

HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $46 Price Target

People Also Watch

Nexstar Media Group Inc

Integer Holdings Corp

FAQ

What is Alkermes Plc (ALKS) stock price today?

The current price of ALKS is 26.13 USD — it has decreased -1.51 % in the last trading day.

ALKS

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

ALKS News & Events

Events Timeline

News

People Also Watch

FAQ

What is Alkermes Plc (ALKS) stock price today?

What is Alkermes Plc (ALKS)'s business?

What is the price predicton of ALKS Stock?

What is Alkermes Plc (ALKS)'s revenue for the last quarter?

What is Alkermes Plc (ALKS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Alkermes Plc (ALKS)'s fundamentals?

How many employees does Alkermes Plc (ALKS). have?

What is Alkermes Plc (ALKS) market cap?